GSK plc (GSK) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GSK Revenue Growth
Revenue Breakdown (FY 2022)
GSK's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
GSK Revenue Analysis (2014–2025)
As of May 7, 2026, GSK plc (GSK) generated trailing twelve-month (TTM) revenue of $32.78 billion, reflecting modest growth of +1.5% year-over-year. The most recent quarter (Q1 2026) recorded $7.63 billion in revenue, down 11.5% sequentially.
Looking at the longer-term picture, GSK's 5-year compound annual growth rate (CAGR) stands at +6.0%, indicating steady revenue expansion. The company achieved its highest annual revenue of $33.75 billion in 2019.
Revenue diversification analysis shows GSK's business is primarily driven by Sub Total (100%). With over half of revenue concentrated in Sub Total, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AZN (+9.9% YoY), NVS (+5.3% YoY), and SNY (+14.1% YoY), GSK has underperformed the peer group in terms of revenue growth. Compare GSK vs AZN →
GSK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GSKCurrent | $32.8B | +1.5% | +6.0% | 25.5% | |
 AZN | $58.7B | +9.9% | +17.2% | 23.4% | |
 NVS | $54.8B | +5.3% | +1.9% | 31.2% | |
 SNY | $46.7B | +14.1% | +4.6% | 13.6% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% |
GSK Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $32.67B | +4.1% | $23.65B | 72.4% | $8.34B | 25.5% |
| 2024 | $31.38B | +3.5% | $22.33B | 71.2% | $4.02B | 12.8% |
| 2023 | $30.33B | +3.4% | $21.76B | 71.8% | $6.75B | 22.2% |
| 2022 | $29.32B | +18.7% | $19.77B | 67.4% | $6.43B | 21.9% |
| 2021 | $24.70B | +1.4% | $16.53B | 66.9% | $4.36B | 17.6% |
| 2020 | $24.35B | -27.8% | $16.43B | 67.4% | $5.98B | 24.6% |
| 2019 | $33.75B | +9.5% | $21.89B | 64.9% | $6.96B | 20.6% |
| 2018 | $30.82B | +2.1% | $20.58B | 66.8% | $5.48B | 17.8% |
| 2017 | $30.19B | +8.2% | $19.84B | 65.7% | $4.09B | 13.5% |
| 2016 | $27.89B | +16.6% | $18.60B | 66.7% | $2.60B | 9.3% |
Full GSK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GSK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GSK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GSK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGSK — Frequently Asked Questions
Quick answers to the most common questions about buying GSK stock.
Is GSK's revenue growth accelerating or slowing?
GSK revenue growth slowed to +1.5%, below the 5-year CAGR of +6.0%. TTM revenue is $32.8B. The deceleration marks a shift from historical growth rates.
What is GSK's long-term revenue growth rate?
GSK plc's 5-year revenue CAGR of +6.0% reflects the variable expansion pattern. Current YoY growth of +1.5% is near this long-term average.
How is GSK's revenue distributed by segment?
GSK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.